AQR Capital Management’s Elevation Oncology ELEV Stock Holding History

AQR Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-51,672	Closed	-$19K	–	3498
2025 Q2	$19K	Sell	51,672 -5,858	-10%	-$1.96K	﹤0.01%	3285
2025 Q1	$14.9K	Buy	+57,530	New	+$32.8K	﹤0.01%	3135
2024 Q4	–	Sell	-161,422	Closed	-$96.8K	–	2892
2024 Q3	$96.8K	Buy	+161,422	New	+$239K	﹤0.01%	2656

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

AQR Capital Management's ELEV Position: Q3 2025 in Review

AQR Capital Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 51,672 shares — an estimated $19K sold.

AQR Capital Management first reported a position in ELEV in Q3 2024 and held it in 3 quarters. The position peaked at $96.8K in Q3 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

AQR Capital Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
AQR Capital Management sold 51,672 Elevation Oncology shares in Q3 2025, an estimated $19K.
AQR Capital Management first reported a position in Elevation Oncology in Q3 2024 and held it in 3 quarters.
AQR Capital Management's Elevation Oncology position peaked at $96.8K in Q3 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.